-
Double Olympic badminton champion Axelsen announces retirement
-
Peru candidate demands vote annulment as count tightens
-
Tom Cruise shares sneak peek of Inarritu comedy 'Digger' at CinemaCon
-
Rosalia caps journey from student to star with Barcelona concerts
-
AI expansion drives up profits at bullish tech giant ASML
-
Hamano strikes as Japan end US winning streak
-
Xi meets Russian FM as leaders flock to China over Middle East war
-
'Industrial' clickbait disinformation targets Australian politics
-
AI-driven chip shortage slowing efforts to get world online: GSMA
-
Kanye West postpones France concert after minister's block call
-
Indonesia, France agree to boost defence industry ties
-
Super Rugby's Moana Pasifika to fold over financial problems
-
Ball hero and villain as Hornets sting Heat to lift NBA postseason curse
-
Capcom looks to extend 'golden age' with sci-fi action game 'Pragmata'
-
Stocks rally, oil extends losses as Trump fans fresh peace hopes
-
Pope to urge peace in Cameroon's conflict zone
-
US lawmaker demands FIFA pay World Cup transport bill amid ticket hikes
-
World Cup 2026: Haiti, a ravaged nation whose heart beats for football
-
'Listening bars' bloom as hottest new nightlife trend
-
Cinema owners welcome back an old friend as Godzilla sequel unveiled
-
QNX and TKMS Collaborate to Bring Canadian Software Innovation to Global Naval Defence Programs
-
Gold IRA Pros and Cons (2026 Guide Released)
-
Tocvan Mobilizes Heavy Equipment at Gran Pilar to Accelerate Trenching and Mine Works
-
InterContinental Hotels Group PLC Announces Transaction in Own Shares - April 15
-
Evotec Appoints Dr. Ingrid Müller as Chief Operating Officer
-
MindMaze Therapeutics Publishes 2025 Annual Report and Corporate Update
-
Peru candidate calls for vote annulment as count tightens
-
Trump says Iran talks may resume as Israel, Lebanon open direct track
-
Ekitike injury 'looks really bad', says concerned Slot
-
Atletico 'ready' for Champions League success at last: Simeone
-
Slot in the firing line as Liverpool blown away by PSG
-
Barcelona deserved to go through but must learn from KO: Flick
-
Konate fumes over Liverpool's rejected penalty in PSG defeat
-
Dembele hails PSG's ability to 'suffer' in win over Liverpool
-
Netflix boss Sarandos has 'constructive' talks with cinema owners
-
Atletico resist Barca to reach Champions League semis
-
Dembele sends PSG past wounded Liverpool into Champions League semis
-
England beat Spain in Women's World Cup qualifier
-
Pope walks in Augustine's footsteps as Algeria trip draws to an end
-
Lebanon, Israel agree to direct negotiations after Washington talks
-
Trump's Fed chair nominee to face Senate confirmation hearing next week
-
Israeli envoy says 'on the same side' with Lebanon after talks in US
-
Noor stars as Chennai keep Kolkata winless in IPL
-
Mascherano departs MLS club Inter Miami
-
Bayern clash to define Real's season, says Bellingham
-
Renault to cut up to 20% of engineers
-
Ukraine says Russian attacks kill seven, including child
-
Salah dropped, Isak starts Liverpool comeback mission against PSG
-
Gucci -- again -- drags down Kering's performance
-
Rolls-Royce unveils ultra-luxury limited series electric car
Jupiter Neurosciences Presenting at the 3rd Annual DealFlow Discovery Conference
JUPITER, FL / ACCESS Newswire / January 27, 2026 / Jupiter Neurosciences, Inc. (NASDAQ:JUNS), a clinical-stage pharmaceutical company developing JOTROL™, a patented resveratrol-based platform for neuroinflammation and healthy aging, today announced that it will participate in the DealFlow Discovery Conference, taking place January 28-29, 2026.
Christer Rosén, Chairman and CEO of Jupiter Neurosciences, will deliver a company presentation and be available for one-on-one investor meetings throughout the event. Learn more about Jupiter Neurosciences at www.jupiterneurosciences.com.
Event Details:
Conference: 3rd Annual DealFlow Discovery Conference
Venue: The Borgata Hotel, Casino & Spa
Location: Atlantic City, NJ
Date: January 28-29, 2026
Investors interested in scheduling a meeting with the Jupiter Neurosciences management team should request an investor pass to attend the conference (no cost to attend).
About Jupiter Neurosciences, Inc.
Jupiter Neurosciences is a clinical-stage pharmaceutical company pursuing a dual-path strategy to address neuroinflammation and promote healthy aging. The Company is advancing a therapeutic pipeline targeting central nervous system (CNS) disorders and rare diseases, while also expanding into the consumer longevity market with its Nugevia product line. Both efforts are powered by JOTROL™, Jupiter's proprietary, enhanced resveratrol formulation that has demonstrated significantly improved bioavailability. Nugevia brings clinical-grade science to the supplement space, supporting mental clarity, skin health, and mitochondrial function. The Company's prescription pipeline is focused broadly on CNS disorders, presently with a Phase IIa in Parkinson's disease, including indications such as Alzheimer's Disease, Mucopolysaccharidoses Type I, Friedreich's Ataxia, and MELAS.
Media Contact:
Christer Rosén
Chairman and CEO
Jupiter Neurosciences, Inc.
[email protected]
SOURCE: DealFlow Events
View the original press release on ACCESS Newswire
L.Mason--AMWN